3 Things You Need to Know
Standard of care
Is of the essence
Patricia: Clinical Trial Patient
When Patricia’s glioblastoma came back after her first surgery, she and her husband both knew it was time to start looking at alternative treatment options. After extensive research, they discovered the hope they were looking for was actually right in their backyard at the Ivy Center in Phoenix.
Tumors We Treat
Common subtypes include astrocytoma, oligodendroglioma, glioblastoma, and gliosarcoma
Also known as ‘secondary’ brain tumors; originate from cancer in another part of the body
Primary brain tumors derived from the lining of the brain, known as the meninges
Arises from the ependymal cells that line the ventricles of the brain and the center of the spinal cord
Arises from small nests of cells near the pituitary stalk at the base of the skull, near the pituitary gland, third ventricle, and optic nerve
Occurs in the pineal region of the brain that may or may not involve the pineal gland
COMMUNITY OF CAREGIVERS
Ivy Brain Tumor Center’s Core Laboratories Awarded Accreditation by the College of American Pathologists
The Ivy Brain Tumor Center, the largest early-phase drug development program for brain cancer in the world, announced that its Pharmacodynamics (PD) Core and Pharmacokinetics (PK) Core laboratories passed their inspection and maintained accreditation by the Accreditation Committee of the College of American Pathologists (CAP).
Diamondbacks GM Mike Hazen and wife give back to support cancer research
The Hazen’s presented a $1.5 million check to doctors, physicians and researchers at the Ivy Brain Tumor Center at the Barrow Neurological Institute. Nicole is receiving treatment and care at the Ivy Center after she was diagnosed in July 2020 with glioblastoma, a rare form of brain cancer.
StacheStrong Raises $340,000 for the Ivy Brain Tumor Center’s Innovative Phase 0 Clinical Trial of Sonodynamic Therapy for Patients with Glioblastoma
StacheStrong, a non-profit devoted to raising funds and awareness for brain cancer research, announced they raised $340,000 for the Ivy Brain Tumor Center at Barrow Neurological Institute.
Ivy Brain Tumor Center Collaborates with GSK on New Phase 0 Clinical Trial to Evaluate Niraparib in Patients with Brain Cancer
The Ivy Center in collaboration with UCSF Department of Neurological Surgery is pleased to announce a new clinical trial of GSK’s niraparib (ZEJULA) – an FDA-approved drug to treat ovarian cancer – for patients with newly diagnosed glioblastoma and recurrent high-grade gliomas.